Q32 Bio sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics for $12 million in upfront and near-term payments, eligible for up to $592 million in total milestone payments plus tiered royalties. This transaction extends the company's cash runway into the second half of 2027 while it advances bempikibart, with SIGNAL-AA Part B topline data on track for mid-2026.
Cyborg Score Rationale
Q32 Bio operates in a challenging pre-revenue biotech space with significant clinical execution risk. While the company secured important non-dilutive funding and maintains a focused pipeline with a promising lead asset, it faces cash burn pressures and near-term clinical trial dependency. The therapeutic area (alopecia areata) offers meaningful commercial opportunity but represents a relatively narrow market focus.
Top Insights
Q32 Bio completed enrollment in Part B of the SIGNAL-AA Phase 2a trial and increased the cohort to 33 patients, with topline data expected in mid-2026.
The company received Fast Track designation for bempikibart, indicating FDA recognition of the unmet medical need.
As of February 20, 2026, the company has 42 employees, indicating a lean operational structure typical of clinical-stage biotech.
Q32 Bio retains its tissue-targeted complement platform including ADX-096 and is evaluating strategic options for remaining programs following the ADX-097 asset sale.
Named Competitors
JAK inhibitors (topical) — Approved treatments for alopecia areata; established but with tolerability concerns
Dupilumab and similar biologics — Immunomodulatory therapies being explored for alopecia areata
Other IL-7R antagonists in development — Similar mechanism of action targeting adaptive immune pathways
Recent Developments
(Feb 2026) Management to present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
(Dec 2025) Sold Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics for $12M upfront plus up to $592M in milestone payments
(Oct 2025) Completed enrollment in SIGNAL-AA Part B and expanded cohort to 33 patients based on patient demand
Open the full interactive Q32 Bio Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.